RxDoctor Payments Data

Curtis Dalili, MD

Internal Medicine · Vero Beach, FLNPI 1972500585

Payments from drug & device makers

$98in general payments, 2019–2025

Across 6 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$39
  • Dexcom, Inc.$31
  • GSK$14
  • Novo Nordisk$13

What the payments were for

  • Food & beverage$98100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC2$39
Dexcom, Inc.2$31
GSK1$14
Novo Nordisk1$13

How this compares

$98 in reported general payments places this provider in the 25th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$756,570
Medicare patients
746
Services billed
10,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide170$262,822
EliquisApixaban169$200,934
OzempicSemaglutide48$66,579
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$54,952
XareltoRivaroxaban37$52,479
JanuviaSitagliptin Phosphate35$44,896
JardianceEmpagliflozin29$39,442
Repatha SyringeEvolocumab38$37,752
RybelsusSemaglutide14$37,377
Breo ElliptaFluticasone/Vilanterol36$28,627
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$19,892
FarxigaDapagliflozin Propanediol12$19,465
EntrestoSacubitril/Valsartan13$18,391
VascepaIcosapent Ethyl14$13,355
Spiriva RespimatTiotropium Bromide12$12,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$39$262,822170 claims
Novo NordiskOzempic, Rybelsus$13$103,95662 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$14$103,470128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →